Objectives: To determine the frequency of selecting mutants resistant to ozenoxacin, a des-fluoro-(6)-quinolone active against pathogens involved in skin and skin structure infections, compared with levofloxacin and ciprofloxacin in quinolone-susceptible and -resistant Gram-positive cocci.
Introduction
The prevalence of infections by MRSA has decreased in Europe in recent years; nevertheless, it remains an important public health problem worldwide. Fluoroquinolones are a therapeutic option against Gram-positive bacteria, including MRSA and MSSA strains. 1 However, this therapy has led to the selection of highly resistant strains during and after therapy owing to mutations in the quinolone resistance-determining region (QRDR). This compromised activity of quinolones and other antimicrobial agents against MRSA has determined the need to design new molecules to treat infections by resistant strains. 2 Ozenoxacin belongs to a new generation of non-fluorinated quinolones and has currently completed Phase III clinical trials for the topical treatment of skin and soft tissue infections. Recent studies have shown that ozenoxacin has excellent in vitro antibacterial activity against Gram-positive cocci, including quinolone-resistant (QR) strains with mutations in the QRDR, being 3-to 321-fold more active than other quinolones. 3 This strong in vitro activity of the new quinolones is probably based on improved affinity for the DNA gyrase and topoisomerase IV targets, creating more potent antibiotic and decreasing the in vitro selection of mutants and the emergence of spontaneous resistant mutants in clinical settings. 4 -6 We determined the frequency of selection of mutants resistant to ozenoxacin compared with levofloxacin and ciprofloxacin in quinolone-susceptible (QS) and QR Gram-positive strains, with and without pre-existing mutations in the QRDR. 
Materials and methods

Bacterial strains
We studied 49 QR and QS Gram-positive clinical isolates collected at the Hospital Clinic of Barcelona, Spain, from 2009 to 2010. The microorganisms tested included MSSA (n ¼ 9), MRSA (n ¼ 5), methicillin-susceptible Staphylococcus epidermidis (MSSE; n ¼ 8), methicillin-resistant Staphylococcus epidermidis (MRSE; n¼5), Streptococcus pyogenes (n¼8), Streptococcus agalactiae (n¼8) and Enterococcus faecium (n¼6).
Susceptibility testing
Microdilution assays for ozenoxacin (Ferrer Internacional S.A.), levofloxacin and ciprofloxacin (Sigma-Aldrich, St Louis, MO, USA) were determined as described by Ló pez et al. 3 
Determination of mutant frequency
The selection of resistant mutants was performed by the single-step method described by Billal et al. 7 Briefly, parent strains were grown in antibiotic-free Mueller -Hinton broth at 378C for 18 h. Approximately 10 8 -10 10 cfu/mL of each strain was inoculated in duplicate onto Mueller -Hinton agar plates containing the selected antibacterial agent at 2×, 4× and 8× MIC of ozenoxacin, levofloxacin or ciprofloxacin. The plates were read at 24 and 48 h. The frequency of resistant mutants selected by each fluoroquinolone was calculated as the ratio of the number of bacteria growing divided by the number of bacteria in the original inoculum, which was calculated by plating several dilutions of the original inoculum.
PCR amplification and sequencing
The QRDRs of both parental and mutant strains were amplified by PCR and sequenced by Beckman Coulter Inc. (UK) as described elsewhere. 3 
Results
The frequencies of mutants resulting from single-step mutations after exposure to ozenoxacin, levofloxacin and ciprofloxacin in the most representative strains in the study are shown in Tables 1  and 2 .
The frequency of single-step mutations for ozenoxacin in all the MSSA strains was low in comparison with levofloxacin and ciprofloxacin, with the mean rates of resistance being .10 210 for ozenoxacin, 1.7×10
28 for levofloxacin and 1×10 28 for ciprofloxacin. Analysis of the mutants selected with ozenoxacin showed a slight increase in the MIC in relation to the parental strain, even in the mutant strain 440, which acquired a single substitution in GyrA (Ser-80 Tyr). In contrast, ozenoxacin did not select mutants in any of the QS-MSSA strains compared with levofloxacin and ciprofloxacin. In these mutants we observed a 16-to 128-fold increase in the MIC of levofloxacin and a 512-to 1024-fold increase in the MIC of ciprofloxacin. The most common change in the QRDR was Ser-80 Tyr in GrlA (Table 1) .
The mutant selection rate was greater for ozenoxacin than that for ciprofloxacin in MRSA strains, with a mean rate of resistance of .10 28 for ozenoxacin and .10 29 for ciprofloxacin. Only one mutant strain was selected in the presence of levofloxacin, with a mutation frequency of 6.7×10
210 . The maximum MIC value for mutant strains was 8 mg/L for ozenoxacin (strain 126, with no new mutation in the QRDR) and 500 and 250 mg/L for levofloxacin and ciprofloxacin (strain 828, with a new mutation, Ser-80 Phe/Leu, in GrlA), being 250-and 125-fold higher than the corresponding MIC of ozenoxacin, respectively (Table 1) .
Although ozenoxacin and ciprofloxacin selected mutants in the MSSE strains, the mean selection rate was lower for ozenoxacin (.10 29 ) than ciprofloxacin (4.5×10 28 ). The mutant strains showed maximum MIC values of 8 mg/L for ozenoxacin. In contrast, the MIC of ciprofloxacin was 512 mg/L. No new mutations were observed in the QRDR target genes in any of the mutants obtained.
Mutant selection was lower for ozenoxacin than ciprofloxacin in all the MRSE strains, ranging from 1.5×10 210 to 10 29 and from 2.9×10 210 to 7.6×10 29 , respectively. The MIC values for the mutant strains selected on ozenoxacin and ciprofloxacin varied from 4 to 16 mg/L and from 64 to 128 mg/L, respectively. A single mutation in the grlA gene at amino acid codon Ser-80 Tyr was only observed in a mutant strain selected with ciprofloxacin. Levofloxacin did not select mutant strains in any of the S. epidermidis strains studied.
The selection frequency of mutants in S. pyogenes strains was similar for ozenoxacin and levofloxacin (10 211 ), but lower than that observed with ciprofloxacin 6.1×10
210 . The mutant strains selected with ozenoxacin or levofloxacin presented an MIC 2-fold higher than the MICs for the respective parental strains and 8-and 16-fold higher, respectively, than the values obtained with ciprofloxacin. Analysis of the QRDR in two mutant strains (165 and 168) selected on levofloxacin and ciprofloxacin showed changes in ParC at amino acids Asp-83 Tyr and Ser-89 Ile, respectively (Table 2) .
Regarding the S. agalactiae strains, the mean resistance rate was similar in ozenoxacin and levofloxacin (5.3×10 210 and 4.9×10 210 , respectively), but lower than that observed with ciprofloxacin (1.3×10
29
). Interestingly, a mutant strain selected with ozenoxacin exhibited an MIC 250-fold higher than that for the parental strains (0.03 -8 mg/L). Furthermore, new mutations were not observed in the target genes of this mutant strain. In contrast, levofloxacin-selected resistant mutant strains with the acquisition of a single mutation in the parC gene (amino acid codon Ser-79 Phe) generated an increase in the MIC value from 1 to 128 mg/L (Table 2) .
Mutant strains of E. faecium were obtained by selection with ozenoxacin and ciprofloxacin, with a similar mean rate of 3.2×10 29 and 4.5×10 29 , respectively. A slight increase in the MIC did not result in acquisition of new mutations in the QRDR. Furthermore, mutants selected on levofloxacin were not observed in strains of E. faecium.
Discussion
Ozenoxacin has excellent activity against the main microorganisms isolated in skin and soft tissue infections. Based on the strong activity of ozenoxacin, our data suggest that this antibiotic selected mutants less frequently than ciprofloxacin (except in MRSA strains), but with a similar frequency to that observed with levofloxacin in all the study strains. It is of note that ozenoxacin did not select mutants in QS-MSSA and -MRSE strains. In addition, differences in selection frequencies by ozenoxacin between MSSA and MRSA have been shown that can, at least in part, explain some reports concerning the fact that exposure to quinolones in the clinical setting was a significant risk factor for the Ló pez et al.
isolation of MRSA, but not MSSA. 8 Moreover, previous studies have hypothesized that the low selection of mutants by ozenoxacin is caused by substitutions at C-8 and C-7, which contribute to the emergence of resistant strains. 9 For all stains studied, the increase in the MIC in the mutant strains obtained was ≤17-fold (except in one strain with an increase of 250-fold) for ozenoxacin and 1-to 128-fold for levofloxacin and 1-to 1024-fold for ciprofloxacin, with the MIC values being ≤16 mg/L of ozenoxacin and ≤512 mg/L of levofloxacin and ciprofloxacin. These results agree with previous reports on the new anti-staphylococcal quinolones, such as delafloxacin, nemonoxacin, NXL-101, nadifloxacin, WCK 1734 and WCK 771, which showed a lower mutation frequency compared with other quinolones, and found that the MICs in mutant strains were not altered with respect to the parental strains. 1,10 -13 Interestingly, ozenoxacin could select, albeit with a low frequency, an additional mutation in the parC gene in the amino acid codon Ser-80 of MSSA and MRSA strains with a known preexisting mutation of the gyrA gene, resulting in decreased susceptibility similar to that described by Sanfilippo et al.
14 Nonetheless, Spontaneous mutants in the S. pyogenes, S. agalactiae and E. faecium strains selected with ozenoxacin, levofloxacin and ciprofloxacin did not show additional mutations in the QRDR, except for two S. pyogenes strains selected with levofloxacin (Asp-83 Tyr in ParC) and ciprofloxacin with a previously undescribed novel mutation (Ser-89 Ile in ParC). Several reports have demonstrated that changes to phenylalanine at amino acid codon Ser-81 in GyrA and amino acid codon Ser-79 in ParC are the primary mechanism of the loss of susceptibility to fluoroquinolones. 7, 16, 17 However, this new mutation in the QRDR may also be involved in the acquisition of resistance.
The low frequency of spontaneous resistant mutant strains caused by ozenoxacin in both susceptible and resistant strains with pre-existing mutations in the QRDR indicates that this quinolone is an excellent therapeutic alternative for the treatment of skin infections.
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